No Script

Please Wait...

Al-Ahed Telegram

French Activist on Trial after Leading Boycott against “Israeli” Pharmaceutical Company

French Activist on Trial after Leading Boycott against “Israeli” Pharmaceutical Company
folder_openZionist Entity access_timeone month ago
starAdd to favorites

By Staff, Agencies

French activist Olivia Zemor has gone on trial in Lyon after making an online appeal in 2016 for a boycott of Israeli pharmaceutical giant Teva company.

She appeared in court on March 16 over publishing a call by Collectif Palestine 69 on EuroPalestine website, urging readers to boycott Teva, the largest “Israeli” pharmaceutical corporation by market value.

Zemor, an active advocate of the Boycott, Divestment, and Sanctions [BDS] movement against the “Israeli” entity, was sued for "defamation" by Teva after she accused the company of complicity in apartheid and occupation.

In comments to French newspaper Le Courrier de l'Atlas, she said, "Through its financial contribution to ‘Israel’, this pharmaceutical giant contributes to the financing of military operations in Gaza and to the development of colonization in the West Bank and East Jerusalem [al-Quds], in defiance of the rights of the Palestinian people and of international resolutions."

Therefore, she added, it is necessary to call for the company's boycott.

Zemor said the “Israeli” entity seeks the extinction of the Palestinian people and denies the Palestinian people's human rights. She has been denied entry into the entity on several occasions.

However, Frederic Jeannin, lawyer for the pharmaceutical company, denied the accusation, claiming that "Teva is not involved in a geopolitical, ethnic or religious conflict, and these actions hamper its economic activity."

On the day of Zemor's trial, activists gathered outside the courtroom to condemn the French government's attempts to silence criticism of the “Israeli” entity and those who speak out against the oppression of Palestinians.

They argue that the European Court of Human Rights last year affirmed the right to boycott the “Israeli” entity and that this ruling invalidates the French prosecution of Zemor, who is the president of the EuroPalestine solidarity group.

French Justice Minister Eric Dupond-Moretti is accused of “a blatant violation of the decision” by distributing a circular to prosecutors urging them to take action against activists supporting the BDS campaign.

Teva, one of the world’s largest manufacturers of generic drugs, provides millions of pounds in tax revenue to the “Israeli” regime and its military.

The company is accused of “joining hands with the French state to aggressively seek to shut down and silence international voices of conscience for exposing corporate complicity and profiteering from the ‘Israeli’ occupation regime.”

People have been asked to show solidarity with Zemor by writing to French embassies and consulates and holding protests outside them.

Palestinians have for decades called on civil campaigns against the “Israeli” entity, organized under the BDS umbrella.

The BDS movement was initiated in 2005 by over 170 Palestinian civil society organizations, unions, as well as cultural and rights groups, including all major political parties, trade and academic unions that were pushing for “various forms of boycott against ‘Israel’ until it meets its obligations under international law.”

Thousands of volunteers worldwide have since then joined the nonviolent campaign, which calls for people and groups across the world to cut economic, cultural and academic ties to Tel Aviv, to help promote the Palestinian cause.

The “Israeli” entity claims that the movement is a strategic threat and accuses it of anti-Semitism – a claim that activists firmly deny, calling it an attempt to discredit them.

The BDS, which adheres to peaceful resistance, intends to exert pressure on the “Israeli” regime to adhere to international law and human rights by lobbying various states, institutions and individuals to understand its oppression of Palestinians and take action as a result.

Comments